Prediction of Nonsentinel Lymph Node Metastasis in Malignant MelanomaCADILI, Ali; SMYLIE, Michael; DANYLUK, John et al.The Journal of surgical research (Print). 2009, Vol 154, Num 2, pp 324-329, issn 0022-4804, 6 p.Article

Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomasPARNEY, Ian F; CHANG, Lung-Ji; FARR-JONES, Maxine A et al.Journal of neuro-oncology. 2006, Vol 78, Num 1, pp 71-80, issn 0167-594X, 10 p.Article

Erlotinib in previously treated non-small-cell lung cancerSHEPHERD, Frances A; PEREIRA, José Rodrigues; VAN KOOTEN, Maximiliano et al.The New England journal of medicine. 2005, Vol 353, Num 2, pp 123-132, issn 0028-4793, 10 p.Article

Randomized phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancerDOUILLARD, Jean-Yves; PESCHEL, Christian; HUMPHREY, Jeffrey et al.Lung cancer. 2004, Vol 46, Num 3, pp 361-368, issn 0169-5002, 8 p.Article

A population-based study of cutaneous melanoma in Alberta, Canada (1993-2002)METELITSA, Andrei I; DOVER, Douglas C; SMYLIE, Michael et al.Journal of the American Academy of Dermatology. 2010, Vol 62, Num 2, pp 227-232, issn 0190-9622, 6 p.Article

Radioiodinated N-[3-(4-morpholino)propyl]-N-methyl-2-hydroxy-5-iodo-3-methylbenzylamine (ERC9) : a new potential melanoma imaging agentSALOPEK, Thomas G; SCOTT, John R; JOSHUA, Alummoottil V et al.European journal of nuclear medicine. 2001, Vol 28, Num 4, pp 408-417, issn 0340-6997Article

Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced MelanomaRIBAS, Antoni; KEFFORD, Richard; LORIGAN, Paul et al.Journal of clinical oncology. 2013, Vol 31, Num 5, pp 616-622, issn 0732-183X, 7 p.Article

Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced Breast CancerPEGRAM, Mark D; PIENKOWSKI, Tadeusz; RIVA, Alessandro et al.Journal of the National Cancer Institute. 2004, Vol 96, Num 10, pp 759-769, issn 0027-8874, 11 p.Article

Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: A trial of the national Cancer Institute of Canada-Clinical Trials Group and the european Organization for Research and Treatment of CancerSHEPHERD, Frances A; GIACCONE, Giuseppe; KRZAKOWSKI, Maciej et al.Journal of clinical oncology. 2002, Vol 20, Num 22, pp 4434-4439, issn 0732-183X, 6 p.Article

Interleukin-21 Has Activity in Patients With Metastatic Melanoma: A Phase II StudyPETRELLA, Teresa M; TOZER, Richard; HAGERMAN, Linda et al.Journal of clinical oncology. 2012, Vol 30, Num 27, pp 3396-3401, issn 0732-183X, 6 p.Article

Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung CancerROSS, Helen J; BLUMENSCHEIN, George R; LEOPOLD, Lance et al.Clinical cancer research (Print). 2010, Vol 16, Num 6, pp 1938-1949, issn 1078-0432, 12 p.Article

Management of Malignant Melanoma : Best PracticesSMYLIE, Michael; CLAVEAU, Joël; ALANEN, Kenneth et al.Journal of cutaneous medicine and surgery. 2009, Vol 13, Num 2, pp 55-73, issn 1203-4754, 19 p.Article

Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy : National cancer institute of canada clinical trials group study BR.20ARNOLD, Andrew M; SEYMOUR, Lesley; GOSS, Glen-Wood et al.Journal of clinical oncology. 2007, Vol 25, Num 27, pp 4278-4284, issn 0732-183X, 7 p.Article